BHVN — Biohaven Ltd. Stock Price, Chart & AI Report

Neutral Jan 15, 2026 • 02:48 UTC Benzinga • Mohd Haider

Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should Know

Biohaven shares surged 6.65% in regular trading and 3.42% in after-hours trading following an investor presentation at the J.P. Morgan Healthcare Conference. The company presented Phase 1 data for BHV-1400 showing significant reductions in IgA nephropathy markers and clinical improvements in patients. Multiple catalysts are expected in 2026, including Phase 2 obesity trial results, pivotal epilepsy trial results, and initiation of trials for other candidates. However, the stock has declined 67.11% over the past 12 months and is trading near its 52-week lows.

BHVN biotech clinical trial data Phase 1 results investor presentation J.P. Morgan Healthcare Conference pipeline catalysts stock momentum

Sentiment note

While the company presented positive clinical data and has multiple catalysts expected in 2026, the stock has experienced a significant 67.11% decline over 12 months and is trading near 52-week lows. The near-term positive momentum is offset by longer-term weakness and the company's position closer to lows than highs, suggesting cautious optimism rather than strong bullish sentiment.

Negative Dec 26, 2025 • 14:26 UTC Benzinga • Rishabh Mishra

Stock Market Today: Dow Jones, S&P 500, Nasdaq Futures Decline After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus (UPDATED)

U.S. stock futures declined on Friday following Wednesday's gains, with major indices showing modest losses. Key movers included Nvidia rising on a licensing agreement with Groq, Dynavax surging 38% on Sanofi acquisition news, Sobr Safe dropping 16% after announcing a private placement, and Biohaven plummeting 14% after a failed clinical trial. Economist Justin Wolfers cautioned that U.S. market gains are lagging global markets significantly.

NVDA DVAX SOBR DTCK stock market futures S&P 500 Dow Jones Nasdaq

Sentiment note

Stock slumped 14.06% after Phase 2 proof-of-concept study of BHV-7000 in major depressive disorder failed to meet its primary endpoint, representing a significant clinical setback.

Positive Dec 2, 2025 • 18:00 UTC GlobeNewswire Inc. • Delveinsight

Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight

The migraine therapeutics market is experiencing strong growth, with over 30 companies developing innovative treatments targeting migraine through advanced therapies like CGRP inhibitors and gepants, supported by improved diagnostic recognition and patient awareness.

AEON BHVN migraine clinical trials therapeutics CGRP inhibitors pipeline

Sentiment note

Initiated pivotal Phase II study for potential first-in-class oral migraine treatment BHV-2100

Negative Nov 19, 2025 • 22:15 UTC The Motley Fool • Robert Izquierdo

Biohaven's Chief Accounting Officer Scooped Up 17,000 Shares. Is the Stock a Buy?

Biohaven's Chief Accounting Officer George Clark purchased 17,000 shares despite the company facing challenges, including FDA rejection of its lead drug and significant quarterly losses. The stock is currently not recommended for investment due to precarious business outlook.

BHVN biotechnology insider trading FDA rejection clinical-stage stock purchase

Sentiment note

Company experienced FDA drug rejection, substantial quarterly net losses ($173.4M), stock price dropped significantly from $47.75 to around $9, and lacks current revenue generation. Despite insider stock purchase, the overall business outlook appears unstable.

Neutral Oct 15, 2025 • 11:00 UTC GlobeNewswire Inc. • Zvonimir Vrselja, M.D., Ph.D.

Bexorg Raises $42.5M to Transform CNS Drug Development with World’s First Integrated AI and Whole-Human Brain Platform

Bexorg, a biotech startup, secured $42.5M in funding to develop an AI-powered platform for central nervous system drug discovery using whole human brain data, aiming to reduce the historically high clinical trial failure rates in CNS drug development.

BHVN AI drug discovery CNS neuroscience biotech funding

Sentiment note

Engaged in a research collaboration with Bexorg, indicating potential interest in the company's technology

Negative Sep 29, 2025 • 17:35 UTC Benzinga • Benzinga Staff Writer

10 Health Care Stocks With Whale Alerts In Today's Session

Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.

ALT ARCT BHVN CNC health care options trading whale alerts stock market

Sentiment note

Bearish put option sweep indicating potential stock decline

Negative Sep 12, 2025 • 14:00 UTC GlobeNewswire Inc. • Rosen Law Firm

BHVN FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Biohaven Ltd. Investors to Secure Counsel Before Important September 12 Deadline in Securities Class Action – BHVN

Rosen Law Firm is notifying Biohaven Ltd. investors about a securities class action lawsuit alleging false statements regarding drug development prospects for troriluzole and BHV-7000.

BHVN securities class action lawsuit drug development investor rights

Sentiment note

The lawsuit alleges the company made false and misleading statements about the regulatory prospects and clinical efficacy of its drug candidates, which likely negatively impacted investor confidence

Negative Sep 11, 2025 • 20:00 UTC GlobeNewswire Inc. • Bronstein, Gewirtz & Grossman Llc

BHVN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biohaven Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against Biohaven Ltd. alleging false and misleading statements about drug development prospects for troriluzole and BHV-7000, potentially impacting the company's business and financial condition.

BHVN class action securities lawsuit drug development regulatory approval

Sentiment note

Lawsuit alleges company made materially false statements about drug regulatory prospects and clinical efficacy, suggesting potential misrepresentation of business operations and potential financial harm to investors

Negative Sep 11, 2025 • 16:43 UTC Benzinga • Business Wire

Deadline Soon: Biohaven Ltd. (BHVN) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Law firm Frank R. Cruz is alerting Biohaven Ltd. investors about an upcoming September 12, 2025 deadline to participate in a securities fraud class action lawsuit, stemming from multiple stock price drops related to drug development setbacks.

BHVN securities fraud lawsuit drug development FDA clinical trials

Sentiment note

Multiple negative events including FDA rejection of drug applications, failed clinical trials for troriluzole and BHV-7000, and significant stock price declines (22.6%, 13.8%, 15.2%, and 19.5% drops in different periods)

Negative Sep 10, 2025 • 14:00 UTC GlobeNewswire Inc. • Pomerantz Llp

Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers – BHVN

Pomerantz Law Firm filed a class action lawsuit against Biohaven Ltd. alleging false and misleading statements about drug trial results for troriluzole and BHV-7000, which negatively impacted stock prices.

BHVN securities lawsuit drug development FDA rejection clinical trials

Sentiment note

Multiple negative events including FDA rejection of troriluzole NDA, failed clinical trial for BHV-7000, withdrawal of European drug application, and significant stock price declines (22.61%, 13.77%, 15.21%, 19.53% drops)

Negative Sep 9, 2025 • 23:21 UTC GlobeNewswire Inc. • Rosen Law Firm

BHVN FINAL DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Biohaven Ltd. Investors to Secure Counsel Before Important September 12 Deadline in Securities Class Action – BHVN

Rosen Law Firm is alerting Biohaven Ltd. investors about a September 12, 2025 deadline for a securities class action lawsuit regarding allegedly false statements about drug development prospects.

BHVN securities class action lawsuit drug development regulatory approval

Sentiment note

The lawsuit alleges the company made false and misleading statements about regulatory prospects for troriluzole and BHV-7000, suggesting potential misrepresentation of drug development data and potential negative impact on business and financial condition

Negative Sep 9, 2025 • 21:40 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

BIOHAVEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Biohaven Investors of the September 12th Deadline to File in the Class Action Lawsuit

A class action lawsuit has been filed against Biohaven Ltd. alleging false and misleading statements about drug regulatory prospects and clinical efficacy during the period of March 24, 2023 to May 14, 2025.

BHVN class action lawsuit securities regulatory approval drug development

Sentiment note

Lawsuit alleges company made materially false statements about drug regulatory prospects for troriluzole and BHV-7000, suggesting potential misrepresentation of clinical data and business prospects